Retatrutide TRIUMPH-1 Results Published: Phase 3 Data Confirm 25% Average Weight Loss

What Happened

The full, peer-reviewed results of TRIUMPH-1, the pivotal late-stage trial of retatrutide, were published in the New England Journal of Medicine on September 30, 2026 — confirming that Eli Lilly's investigational triple agonist produced some of the largest weight reductions ever recorded in a Phase 3 obesity trial.

Participants receiving the highest of three tested doses lost an average of 25 percent of their body weight over 80 weeks. In a pre-specified extension to 104 weeks, average weight loss reached 30 percent — a magnitude rivaling bariatric surgery. More than one-third of participants lost at least 30 percent of their body weight.

The trial randomized 2,339 adults across 131 sites in 11 countries to one of three retatrutide doses or placebo; average starting weight was roughly 113 kg with a mean BMI near 40. The readout went beyond the scale:

• Knee osteoarthritis pain fell by up to 62 percent among the 574 participants with obesity-linked knee OA
• Obstructive sleep apnea events per hour dropped by up to 57 percent among the 243 participants with that condition
• Blood pressure, triglycerides, and LDL cholesterol improved across dose groups
• More than 90 percent of participants who began with prediabetes had moved beyond that threshold by the end

Who Is Affected

• Obesity researchers, who now have a peer-reviewed, placebo-controlled Phase 3 benchmark
• Clinicians — publication is not approval; retatrutide stays unavailable outside trials
• Gray-market buyers: nothing changes legally, and no vial sold online comes from a pharmaceutical supply chain
• Rival drug developers, whose candidates will now be measured against these numbers

Timeline

• 2021–2022: First-in-human testing establishes the triple-agonist profile
• 2023: Phase 2 results report up to roughly 24 percent average weight loss; the TRIUMPH Phase 3 program launches
• May 2026: Positive topline TRIUMPH-1 results announced
• September 30, 2026: Full peer-reviewed results published, including extension and comorbidity analyses
• Ahead: Further TRIUMPH readouts in diabetes and cardiovascular disease populations, then regulatory filings

What This Means for Researchers

Three points stand out. First, published figures are more conservative than the topline announcement — the peer-reviewed numbers differ modestly from May's because of how the analyses treat adherence and treatment changes, so always check which statistical framework a headline number comes from. Second, there is no head-to-head comparison yet: TRIUMPH-1 was placebo-controlled, so claims of superiority over approved dual agonists remain untested. Third, safety questions stay open — gastrointestinal effects were typical of the incretin class, dizziness with low blood pressure clustered in participants on antihypertensives, and the trial recorded ten cardiovascular events and ten pancreatitis reports (including placebo cases), too few to assess rare risks.

As coverage amplifies, gray-market interest in "retatrutide" will spike further, even though it remains legally available only to trial participants.

How to Verify Your Peptides

No product sold as retatrutide today is legally marketed anywhere in the world. For any research compound, verification is non-negotiable:

• Require a batch-specific certificate of analysis, never a reused generic PDF
• Confirm purity by HPLC and identity by LC-MS, ideally from an independent lab
• Check actual fill weight, not label claims

Our guides cover how third-party testing works, HPLC versus LC-MS methods, and identity, purity, and fill-weight reports.

Safe Alternatives

Approved pharmaceutical references exist for comparison: semaglutide and tirzepatide are documented alongside the investigational candidate in our retatrutide research profile and the wider research-grade peptide landscape. Start with our vendor directory.

Sources

Peer-reviewed literature (New England Journal of Medicine, 2026); industry reports; regulatory announcements.